General Information of the Compound
| Compound ID |
CP0044275
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
9-Chloro-2-furan-2-yl-[1,2,4]triazolo[1,5-c]quinazolin-5-ylamine
Show/Hide
|
||||||||||||||||||
| Synonyms |
104615-18-1
CGS-15943
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C13H8ClN5O
|
||||||||||||||||||
| Molecular Weight |
285.694
|
||||||||||||||||||
| Canonical SMILES |
Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C13H8ClN5O/c14-7-3-4-9-8(6-7)12-17-11(10-2-1-5-20-10)18-19(12)13(15)16-9/h1-6H,(H2,15,16)
Show/Hide
|
||||||||||||||||||
| InChIKey |
MSJODEOZODDVGW-UHFFFAOYSA-N
|
||||||||||||||||||
| CAS |
104615-18-1
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00840, Adenosine receptor A1
Protein ID: PT00862, Adenosine receptor A2a
Cell-based Assay
Protein ID: PT01278, Adenosine receptor A2b
Cell-based Assay
Protein ID: PT01279, Adenosine receptor A3
Cell-based Assay
Protein ID: PT02805, CREB-binding protein
Protein ID: PT01065, Serine/threonine-protein kinase mTOR
Clinical Information about the Compound
Drug 1 ( CGS-15943 )
| Drug Name | CGS-15943 | ||
|---|---|---|---|